

## Antigenic extracts of *Leishmania braziliensis* and *Leishmania amazonensis* associated with saponin partially protects BALB/c mice against *Leishmania chagasi* infection by suppressing IL-10 and IL-4 production

Rafaella FQ Grenfell<sup>1,2/+</sup>, Eduardo A Marques-da-Silva<sup>2</sup>, Miriam C Souza-Testasica<sup>2</sup>, Eduardo AF Coelho<sup>3,4,5</sup>, Ana Paula Fernandes<sup>3</sup>, Luís Carlos C Afonso<sup>2</sup>, Simone A Rezende<sup>2,6</sup>

<sup>1</sup>Laboratório de Esquistossomose, Instituto de Pesquisas René Rachou-Fiocruz, Av. Augusto de Lima 1715, 30.190-002 Belo Horizonte, MG, Brasil <sup>2</sup>Coordenadoria de Ciências Biológicas, Instituto Federal de Minas Gerais e Laboratório de Imunoparasitologia

<sup>6</sup>Departamento de Análises Clínicas, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil

<sup>4</sup>Setor de Patologia Clínica, Colégio Técnico <sup>3</sup>Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas

<sup>5</sup>Departamento de Microbiologia, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil

*This study evaluated two vaccine candidates for their effectiveness in protecting BALB/c mice against Leishmania chagasi infection. These immunogenic preparations were composed of Leishmania amazonensis or Leishmania braziliensis antigenic extracts in association with saponin adjuvant. Mice were given three subcutaneous doses of one of these vaccine candidates weekly for three weeks and four weeks later challenged with promastigotes of L. chagasi by intravenous injection. We observed that both vaccine candidates induced a significant reduction in the parasite load of the liver, while the L. amazonensis antigenic extract also stimulated a reduction in spleen parasite load. This protection was associated with a suppression of both interleukin (IL)-10 and IL-4 cytokines by spleen cells in response to L. chagasi antigen. No change was detected in the production of IFN- $\gamma$ . Our data show that these immunogenic preparations reduce the type 2 immune response leading to the control of parasite replication.*

Key words: vaccine - *Leishmania chagasi* - *Leishmania braziliensis* - *Leishmania amazonensis* - IL-10 - IL-4

Leishmaniasis is a spectrum of diseases caused by infection with different *Leishmania* species that range from self-limiting cutaneous leishmaniasis to visceral leishmaniasis (VL). VL, also known as kala-azar, is fatal if not successfully treated. Human infection with *Leishmania chagasi/Leishmania infantum*, the protozoan causing South American VL, ranges from sub-clinical infection to progressive fatal disease (Wilson 1993). Sub-clinical infection results in the development of a cellular immune response that often results in long-term protective immunity against re-infection (Pearson & Sousa 1996), suggesting that a vaccine against leishmaniasis is feasible. Since treatment of VL is difficult and no acceptable vaccine exists against human infection, the development of an effective vaccine would be an important achievement. An ideal vaccine would be one that could offer cross-protection against diverse *Leishmania* species (Campbell et al. 2003).

The involvement of T helper 1 (Th1) and T helper 2 (Th2) subsets with either protection or disease exacerbation has been demonstrated in murine cutaneous leishmaniasis (Heinzel et al. 1989). A similar pattern of Th cell subsets has been shown in some studies for VL (Rhee et al. 2002), mainly because interleukin-4

(IL-4) can regulate macrophage function (Hamilton et al. 1999). Unexpectedly, some studies in animal models have proven that protection in VL is associated with the production of both type 1 and type 2 cytokines (Ghosh et al. 2001, Ramiro et al. 2003, Vilela et al. 2007).

In this study, we evaluated the potential of two freeze-thawed (FT) *Leishmania* antigenic extracts for protection against *L. chagasi* infection. Cross-species protection has been supported in many studies on leishmaniasis (Bebars et al. 2000, Misra et al. 2001, Tonui & Titus 2007). Therefore, we decided to investigate whether subcutaneous immunization with extracts of *Leishmania amazonensis* or *Leishmania braziliensis* could protect BALB/c mice against *L. chagasi* infection. These two antigenic extracts and a purified saponin fraction from the bark extracts of *Quillaja saponaria*, which has been considered a promising adjuvant in numerous prophylactic and therapeutic vaccines, were used in association (Kensil 1996). It is worth noting that the mechanism by which saponin potentiates an immune response remains unclear. Hypotheses have been raised about whether saponin, through lectin-mediated cell membrane interactions, could facilitate the uptake of the antigen into antigen-presenting cells, leading to specific cytokine profiles that enhance T and/or B-cell responses (Kensil 1996, Marciani 2003, Adams et al. 2010).

We decided to evaluate these two species because a tested vaccine composed of *L. amazonensis* along with Bacillus Calmette-Guérin has been effective in the treatment of cutaneous leishmaniasis patients in Venezuela (Convit et al. 2003). Further, a recent vaccine composed

Financial support: FAPEMIG

+ Corresponding author: rafaella@cpqrr.fiocruz.br

Received 23 March 2010

Accepted 20 July 2010

of *L. braziliensis*, sand fly gland extract and saponin was shown to be immunogenic in dogs (Giunchetti et al. 2007, 2008). These species are associated not only with localized cutaneous leishmaniasis, but also with mucocutaneous leishmaniasis and anergic diffuse cutaneous leishmaniasis in Brazil.

This study aimed at evaluating whether these two vaccine candidates, composed of antigens obtained from species responsible for cutaneous and mucocutaneous leishmaniasis, could protect against murine VL caused by *L. chagasi*.

## MATERIALS AND METHODS

**Leishmania parasites and antigens** - The strain of *L. chagasi* used in this study (MHOM/BR/1974/M2682) was kindly provided by Dr Maria Norma de Melo, from the Parasitology Department, Federal University of Minas Gerais (UFMG), Brazil. Promastigotes were grown in Dulbecco's Modified Eagle Medium (DMEM; pH 6.8) supplemented with 20% heat-inactivated foetal bovine serum (FBS), 2 mM L-glutamine, 25 mM HEPES, 50  $\mu$ M 2-mercaptoethanol and 20  $\mu$ g/mL garamicin [DMEM 20% phosphate buffered saline (PBS)] at 25°C. Infectivity was maintained by serial passage through mice. *L. amazonensis* strain PH8 (IFLA/BR/67/PH8) and *L. braziliensis* strain M2903 (MHOM/BR/75/M2903) were grown in Grace's Medium supplemented with 20% FBS, 2 mM L-glutamine and 20  $\mu$ g/mL garamicin. Promastigotes of *L. chagasi*, *L. amazonensis* or *L. braziliensis* were harvested from late-log-phase cultures by centrifugation, washed three times with PBS and disrupted by three rounds of freezing and thawing. The protein contents were estimated (Lowry et al. 1951) and the antigen was frozen at -70°C prior to use. *L. amazonensis* and *L. braziliensis* antigens were used to immunize mice.

**Mice, immunizations and the quantification of parasite load** - Female BALB/c mice (4-6 weeks old) were obtained from Bioterism Center, UFMG, and were maintained at the Central Biotherium, Federal University of Ouro Preto (UFOP). Four BALB/c mice per group, in three independent experiments, were injected weekly with three subcutaneous doses of 100  $\mu$ g of *L. amazonensis* or *L. braziliensis* antigenic extracts together with 50  $\mu$ g of saponin as an adjuvant. Control mice were inoculated with PBS or 50  $\mu$ g of saponin alone. Four weeks later, mice were challenged with  $1 \times 10^7$  promastigotes of *L. chagasi* given intravenously through the lateral tail vein. Five post challenge mice were sacrificed and the spleen and liver parasite loads were determined by quantitative limiting-dilution culture. Quantitative limiting-dilution culture was performed as previously described with some modifications (Marques-da-Silva et al. 2005). Briefly, spleen and liver were harvested and weighed. One fragment of each organ was obtained and weighed separately for parasite quantification. This fragment was homogenized in a tissue grinder, resuspended in 500  $\mu$ L of DMEM containing 20% FBS and plated onto 48-well flat-bottom microtiter plates. Five-fold serial dilutions were performed and, after two weeks of incubation at 25°C, plates were microscopically scored for parasite growth. The number

of parasites was determined from the reciprocal of the highest dilution at which promastigotes could be detected and is expressed as parasites per organ.

**Determination of vaccine-induced cytokine production** - Single-cell suspensions of spleen were obtained by homogenization in a tissue grinder. The erythrocytes were lysed with ammonium chloride lysis buffer and the cells were washed. Cells were then cultured in DMEM (pH 7.2) supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 25 mM HEPES, 50  $\mu$ M 2-mercaptoethanol and 20  $\mu$ g/mL garamicin (DMEM 10% FBS) at  $5 \times 10^6$  cells/mL in 48-well flat-bottom plates without stimuli (ws) or stimulated with 50  $\mu$ g of *L. chagasi* Ag/mL of culture for 72 h. The production of IFN- $\gamma$  and IL-4 was determined by the presence of these cytokines in cell culture supernatant, as measured by enzyme linked immunosorbent assay (ELISA) using specific purified monoclonal antibodies (Afonso & Scott 1993). The production of IL-10 was assayed using a commercial ELISA kit, according to the manufacturer's instructions (Duo Set<sup>®</sup>, R&D Systems).

**Statistical analysis** - Parasite burden data were logarithmically transformed to determine the homogeneity of variance. All data were analyzed using the Kolmogorov-Smirnov normality test. Data with a normal distribution were analyzed by the Student's *t* test.

**Ethics** - This study was approved by the Ethical Committee of the UFOP.

## RESULTS

**Parasite load in liver and spleen** - In order to determine if *L. amazonensis* or *L. braziliensis* antigenic extracts were able to protect BALB/c mice from *L. chagasi* infection, we evaluated the parasite load within the liver and spleen by limiting dilution analyses. Mice that were immunized with FT *L. amazonensis* antigen showed significant reduction in parasite load in the liver and spleen ( $p < 0.05$ ), as shown in Fig. 1. The *L. braziliensis* antigen was also able to reduce the parasite load in the liver but did not significantly decrease the parasite load in the spleen.

**Determination of IFN- $\gamma$ , IL-4 and IL-10 production by spleen cells after vaccination and challenge** - In order to determine if these vaccine candidates could influence the immune response to *L. chagasi*, spleen cells from immunized animals were obtained and incubated with 50  $\mu$ g/mL of FT *L. chagasi* antigen or cultured ws. Fig. 2A shows that although no change in IFN- $\gamma$  production was noted following immunization, spleen cells from animals treated with either vaccine candidate exhibited significantly reduced production of IL-4 (Fig. 2B) and IL-10 (Fig. 2C) as compared to control spleen cells ( $p < 0.05$ ).

## DISCUSSION

In recent years, several efforts have been made to obtain a safe and efficient vaccine against leishmaniasis. Vaccination with live, attenuated parasites has been attempted (Streit et al. 2001, Nylén et al. 2006), although there are several ethical considerations regarding these vaccines. As such, attention has shifted




Fig. 1: liver and spleen parasite load of immunized BALB/c mice challenged four weeks after immunization. BALB/c mice were immunized with the 100  $\mu$ g of freeze-thawed (FT) *Leishmania amazonensis* or FT *Leishmania braziliensis* antigen and 50  $\mu$ g of saponin and challenged by intravenous route with  $1 \times 10^7$  *Leishmania chagasi* late-log-phase promastigotes four weeks after immunization. Five weeks after challenge, mice were sacrificed and their liver (black) and spleen (grey) were harvested for parasite quantification by limiting-dilution quantitative culture. Statistical differences between groups are represented by letters ( $p < 0.05$ ) in comparison with animals from groups: a: saline; b: saponin. Four mice per group were used and the bars represent the mean (log) of three independent experiments + standard deviation. Statistical differences were determined by Student's *t* test.

to the use of recombinant or synthetic antigens, purified fractions or whole antigenic extracts of parasites as an alternative to live parasites. Whole antigenic extract obtained from parasites is a reasonable alternative considering its immunogenicity, cost and safety. Furthermore, any human vaccine will probably require several different antigens and adjuvant to guarantee a satisfactory response by a majority of the population, given its heterogeneity (Handman 2001).

A vaccine against cutaneous leishmaniasis was developed by Mayrink et al. (1979). It was prepared from whole parasite antigens obtained from five stocks of parasites isolated from patients with different forms of leishmaniasis. Subsequently, the same group developed a second vaccine based only on the PH8 strain of *L. amazonensis*. This vaccine has been used in the prevention of disease, as well as serving as an immunotherapeutic agent, thereby demonstrating that administration of the vaccine in association with antimony salts could be therapeutic. Indeed, when compared with conventional therapy, *L. amazonensis* vaccine treatment reduced the time necessary for lesions in patients with cutaneous leishmaniasis to completely heal (Toledo et al. 2001). Furthermore, Mayrink et al. (2006) have shown that the association of a vaccine antigen with antimony salts reduces both the total salt volume and the treatment length, thereby reducing the side effects otherwise associated with the use of antimony salts.

During this study, we evaluated whether antigens from *L. amazonensis* and *L. braziliensis* could provide heterologous protection against *L. chagasi* infection in BALB/c mice. These antigens were used in conjunction with saponin, an adjuvant that has been used in stud-




Fig. 2: IFN- $\gamma$ , interleukin (IL)-4 and IL-10 production by spleen cells after immunization with 100  $\mu$ g freeze-thawed (FT) *Leishmania amazonensis* or FT *Leishmania braziliensis* antigen and 50  $\mu$ g of saponin and challenge with *Leishmania chagasi*. Five weeks after challenge, mice were sacrificed and cytokine production (A: IFN- $\gamma$ ; B: IL-4; C: IL-10) by spleen cells was evaluated. Spleen cells were cultured for 72 h with FT *L. chagasi* antigen (50  $\mu$ g/mL) (FT *L. chagasi* stimuli) or without stimuli. Statistical differences between groups are represented by letters ( $p < 0.05$ ) in comparison with animals from groups: a: saline; b: saponin. Four mice per group were used and the bars represent the mean (log) of three independent experiments + standard deviation. Statistical differences were determined by Student's *t* test.

ies involving VL or cutaneous leishmaniasis in mice and dogs (Santos et al. 2002, Nico et al. 2007, Fernandes et al. 2008, Borja-Cabrera et al. 2010). We found that both vaccine candidates were able to reduce parasite load in the liver, but that only the *L. amazonensis* immunogenic extract reduced the parasite load of the spleen. These data suggest that different mechanisms are utilized to afford protection by these freeze-thawed vaccines.

In mice, Vilela et al. (2007) have shown that a vaccine composed of *L. amazonensis* (PH8 strain) and *Corynebacterium parvum* is able to protect against *L. chagasi* infection. Although this vaccine used antigens derived from *L. amazonensis*, a different pattern of cytokine expression was observed, since in this case protection was associ-



ated with an increase in both type 1 and type 2 cytokines. Studies with *L. braziliensis* have shown that a vaccine composed of FT antigen and saponin may prevent *L. chagasi* infection in dogs (Giunchetti et al. 2007, 2008).

In order to assess the immune response induced by both vaccine candidates, we evaluated the production of cytokines by spleen cells. Although we detected a difference in the pattern of protection between the two organs tested, none of the immunogenic preparations led to increased IFN- $\gamma$  production. In contrast both antigenic preparations resulted in suppressed IL-10 and IL-4 production by spleen cells. That the suppression of cytokines may reduce parasite load has previously been noted in spleen following the immunization of mice with *Leishmania major* antigens and intravenous challenge with *Leishmania donovani*. These mice had reduced IL-4 and IL-10 cytokine levels together with an increase in IFN- $\gamma$  production. This particular cytokine pattern was not observed when the same immunization was performed together with a *L. braziliensis* infection. Why this occurred is a matter of debate. However, certain possibilities seem plausible: first, there may be something inherently different about *L. braziliensis* as compared to *L. donovani* and their interactions with the immune system that elicit distinct levels of protection. For instance, each of these parasites may differ in their ability to induce effector vs. regulatory T cells (Tonui & Titus 2007).

Saponin adjuvant could influence the generation of an immune response at several levels: these may include the mobilization of appropriate antigen-presenting cells to the injected site, enhancing efficient antigen processing and presentation, influencing the cytokine response, including IFN- $\gamma$  and the co-stimulatory signals necessary for an optimal immune response and increasing the recruitment of effector immune cells to the inflammatory areas (Caro et al. 2003, Buendía et al. 2007). The capacity of this adjuvant to elicit a strong CD8 T cell response has also been reported (Newman et al. 1992). These studies emphasize the immunostimulatory capability of saponin that may have led to the improved level of protection found in our study, although saponin alone did not lead to enhanced IFN- $\gamma$  production by spleen cells.

The effect of our vaccines on IL-10 production has been observed in other studies. Uzonna et al. (2004) had shown that vaccination with *L. major* mutants was associated with a decrease in IL-10 and IL-4 production. Similarly, Bhaumik et al. (2009) showed that a vaccine candidate composed of soluble antigen from attenuated *L. donovani* promastigotes was able to provide complete protection against experimental VL and that this protection was associated with a decrease in the production of IL-10. Gomes et al. (2007) showed that, after intranasal immunization with a plasmid expressing the *Leishmania* analogue of the receptors of activated C kinase, BALB/c mice developed lower parasite burdens and had a decrease in IL-10 production. In another study, it was shown that BALB/c mice immunized with a plasmid encoding the *A2* gene were protected against experimental challenge with *L. amazonensis* or *L. donovani* and that this protection was associated with a reduced level of IL-10 production (Zanin et al. 2007). Finally, it is already known that human VL is associated with high levels of IL-10. As such, suppression of this cytokine might be

important for disease because it is involved in the suppression of macrophage activity (Nylén & Sacks 2007).

The role of IL-4 in VL is not as well understood. Some studies have shown that IL-4 is important for granuloma maturation and anti-leishmanial activity in the murine model of *L. donovani* infection (Kemp et al. 1996). In contrast, another study has shown that protection from leishmaniasis is associated with a reduction of type 2 cytokines, including IL-4 (Alves et al. 2009).

The current study shows that immunogenic preparations composed of *L. amazonensis* or *L. braziliensis* partially protect BALB/c mice from intravenous challenge with *L. chagasi* promastigotes and that this protection is associated with a reduction in the level of IL-10 and IL-4 expression. The role played by saponin in a model whereby regulatory cytokines are suppressed is not known and should be the subject of additional investigation. Furthermore, it shows that cross-protection between *Leishmania* species presents a major practical implication because vaccination procedures based on the use of a vaccine from one species will likely protect against different *Leishmania* species.

#### ACKNOWLEDGEMENTS

To Dr Alexandre Barbosa Reis, for his assistance.

#### REFERENCES

- Adams MM, Damani P, Perl NR, Won A, Hong F, Livingston PO, Ragupathi G, Gin DY 2010. Design and synthesis of potent Quilajaja saponin vaccine adjuvants. *J Am Chem Soc* 132: 1939-1945.
- Afonso LC, Scott P 1993. Immune responses associated with susceptibility of C57BL/10 mice to *Leishmania amazonensis*. *Infect Immun* 61: 2952-2959.
- Alves CF, de Amorim IF, Moura EP, Ribeiro RR, Alves CF, Michalick MS, Kalapothakis E, Bruna-Romero O, Tafuri WL, Teixeira MM, Melo MN 2009. Expression of IFN-gamma, TNF-alpha, IL-10 and TGF-beta in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with *Leishmania (Leishmania) chagasi*. *Vet Immunol Immunopathol* 128: 349-358.
- Bebars MA, el Serougi AO, Makled KM, Mikhael EM, Abou Gamra MM, el Sherbiny M, Mohareb AW, Mohammed EA 2000. An experimental vaccine providing heterologous protection for *Leishmania* species in murine model. *J Egypt Soc Parasitol* 30: 137-156.
- Bhaumik SK, Naskar K, De T 2009. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated *Leishmania donovani* promastigotes involves Th1-immunity and down-regulation of IL-10. *Eur J Immunol* 39: 2146-2160.
- Borja-Cabrera GP, Santos FN, Santos FB, Trivellato FA, Kawasaki JK, Costa AC, Castro T, Nogueira FS, Moreira MA, Luvizotto MC, Palatnik M, Palatnik-de-Sousa CB 2010. Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. *Vaccine* 28: 597-603.
- Buendía AJ, Nicolás L, Ortega N, Gallego MC, Martínez CM, Sánchez J, Caro MR, Navarro JA, Salinas J 2007. Characterization of a murine model of intranasal infection suitable for testing vaccines against *C. abortus*. *Vet Immunol Immunopathol* 115: 76-86.
- Campbell K, Diao H, Ji J, Soong L 2003. DNA immunization with the gene encoding P4 nuclease of *Leishmania amazonensis* protects mice against cutaneous leishmaniasis. *Infect Immun* 71: 6270-6278.
- Caro MR, Ortega N, Buendía AJ, Gallego MC, Del Río L, Cuello F,

- Salinas J 2003. Relationship between the immune response and protection conferred by new designed inactivated vaccines against ovine enzootic abortion in a mouse model. *Vaccine* 21: 3126-3136.
- Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M, Villaruel H, Zapata Z, Tomedes I 2003. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-99. *Trans R Soc Trop Med Hyg* 97: 469-472.
- Fernandes AP, Costa MM, Coelho EA, Michalick MS, de Freitas E, Melo MN, Luiz Tafuri W, Resende D de M, Hermont V, Abrantes C de F, Gazzinelli RT 2008. Protective immunity against challenge with *Leishmania (Leishmania) chagasi* in beagle dogs vaccinated with recombinant A2 protein. *Vaccine* 26: 5888-5895.
- Ghosh A, Zhang WW, Matlashewski G 2001. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against *Leishmania donovani* infections. *Vaccine* 20: 59-66.
- Giunchetti RC, Corrêa-Oliveira R, Martins-Filho OA, Teixeira-Carvalho A, Roatt BM, de Oliveira Aguiar-Soares RD, Coura-Vital W, de Abreu RT, Malaquias LC, Gontijo NF, Brodskyn C, de Oliveira CI, Costa DJ, de Lana M, Reis AB 2008. A killed *Leishmania* vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. *Vaccine* 26: 623-638.
- Giunchetti RC, Corrêa-Oliveira R, Martins-Filho OA, Teixeira-Carvalho A, Roatt BM, de Oliveira Aguiar-Soares RD, de Souza JV, das Dores Moreira N, Malaquias LC, Mota e Castro LL, de Lana M, Reis AB 2007. Immunogenicity of a killed *Leishmania* vaccine with saponin adjuvant in dogs. *Vaccine* 25: 7674-7686.
- Gomes DC, Pinto EF, de Melo LD, Lima WP, Larraga V, Lopes UG, Rossi-Bergmann B 2007. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. *Vaccine* 25: 2168-2172.
- Hamilton TA, Ohmori Y, Tebo JM, Kishore R 1999. Regulation of macrophage gene expression by pro- and anti-inflammatory cytokines. *Pathobiology* 67: 241-244.
- Handman E 2001. Leishmaniasis: current status of vaccine development. *Clin Microbiol Rev* 14: 229-243.
- Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM 1989. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. *J Exp Med* 169: 59-72.
- Kemp M, Theander TG, Kharazmi A 1996. The contrasting roles of CD4<sup>+</sup> T cells in intracellular infections in humans: leishmaniasis as an example. *Immunol Today* 17: 13-16.
- Kensil CR 1996. Saponins as vaccine adjuvants. *Crit Rev Ther Drug Carrier Syst* 13: 1-55.
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ 1951. Protein measurement with the Folin phenol reagent. *J Biol Chem* 193: 265-275.
- Marciani DJ 2003. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. *Drug Discov Today* 8: 934-943.
- Marques-da-Silva EA, Coelho EA, Gomes DC, Vilela MC, Masioli CZ, Tavares CA, Fernandes AP, Afonso LC, Rezende SA 2005. Intramuscular immunization with p36 (LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against *Leishmania chagasi* intravenous challenge. *Parasitol Res* 98: 67-74.
- Mayrink W, Botelho AC, Magalhães PA, Batista SM, Lima A de O, Genaro O, Costa CA, Melo MN, Michalick MS, Williams P, Dias M, Caiaffa WT, Nascimento E, Machado-Coelho GL 2006. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. *Rev Soc Bras Med Trop* 39: 14-21.
- Mayrink W, da Costa CA, Magalhães PA, Melo MN, Dias M, Lima AO, Michalick MS, Williams P 1979. A field trial of a vaccine against American dermal leishmaniasis. *Trans R Soc Trop Med Hyg* 73: 385-387.
- Misra A, Dube A, Srivastava B, Sharma P, Srivastava JK, Katiyar JC, Naik S 2001. Successful vaccination against *Leishmania donovani* infection in Indian langur using alum-precipitated autoclaved *Leishmania major* with BCG. *Vaccine* 19: 3485-3492.
- Newman MJ, Wu JY, Gardner BH, Munroe KJ, Leombruno D, Recchia J, Kensil CR, Coughlin RT 1992. Saponin adjuvant induction of ovalbumin-specific CD8<sup>+</sup> cytotoxic T lymphocyte responses. *J Immunol* 148: 2357-2362.
- Nico D, Santos FN, Borja-Cabrera GP, Palatnik M, Palatnik de Sousa CB 2007. Assessment of the monoterpene, glycidic and triterpene moieties' contributions to the adjuvant function of the CP05 saponin of *Calliandra pulcherrima* Benth during vaccination against experimental visceral leishmaniasis. *Vaccine* 25: 649-658.
- Nylén S, Khamesipour A, Mohammadi A, Jafari-Shakib R, Eidsmo L, Noazin S, Modabber F, Akuffo H 2006. Surrogate markers of immunity to *Leishmania major* in leishmanin skin test negative individuals from an endemic area re-visited. *Vaccine* 24: 6944-6954.
- Nylén S, Sacks D 2007. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. *Trends Immunol* 28: 378-384.
- Pearson RD, Sousa AQ 1996. Clinical spectrum of leishmaniasis. *Clin Infect Dis* 22: 1-13.
- Ramiro MJ, Zárate JJ, Hanke T, Rodriguez D, Rodriguez JR, Esteban M 2003. Protection in dogs against visceral leishmaniasis caused by *Leishmania infantum* is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. *Vaccine* 21: 2474-2484.
- Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL, Seder RA 2002. Vaccination with heat-killed *Leishmania* antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses and protection against *Leishmania major* infection. *J Exp Med* 195: 1565-1573.
- Santos WR, de Lima VM, de Souza EP, Bernardo RR, Palatnik M, Palatnik de Sousa CB 2002. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. *Vaccine* 21: 30-43.
- Streit JA, Recker TJ, Filho FG, Beverly SM, Wilson ME 2001. Protective immunity against the protozoan *Leishmania chagasi* is induced by subclinical cutaneous infection with virulent but not avirulent organisms. *J Immunol* 166: 1921-1929.
- Toledo VP, Mayrink W, Gollob KJ, Oliveira MA, Costa CA, Genaro O, Pinto JA, Afonso LC 2001. Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. *Mem Inst Oswaldo Cruz* 96: 89-98.
- Tonui WK, Titus RG 2007. Cross-protection against *Leishmania donovani* but not *L. braziliensis* caused by vaccination with *L. major* soluble promastigote exogenous antigens in BALB/c mice. *Am J Trop Med Hyg* 76: 579-584.
- Uzonna JE, Späth GF, Beverley SM, Scott P 2004. Vaccination with phosphoglycan-deficient *Leishmania major* protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. *J Immunol* 172: 3793-3797.
- Vilela M de C, Gomes DC, Marques-da-Silva E de A, Serafim TD, Afonso LC, Rezende SA 2007. Successful vaccination against *Leishmania chagasi* infection in BALB/c mice with freeze-thawed *Leishmania* antigen and *Corynebacterium parvum*. *Acta Trop* 104: 133-139.
- Wilson ME 1993. Leishmaniasis. *Curr Opin Infect Dis* 6: 331-340.
- Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Silva Costa MM, Rezende SA, Gazzinelli RT, Fernandes AP 2007. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against *Leishmania chagasi* and *Leishmania amazonensis* experimental infections. *Microbes Infect* 9: 1070-1077.